{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-22-000061","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.831644+00:00","generated_at":"2026-06-22T05:36:09.334684+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Krystal Biotech Q3 net loss $29.9M; B-VEC BLA with Priority Review accepted, PDUFA Feb 17, 2023","bullets":["Cash and investments $407M at quarter end; net loss $29.9M ($1.17 per share) vs $15.6M loss in Q3 2021.","FDA accepted B-VEC BLA for dystrophic epidermolysis bullosa with Priority Review; PDUFA target Feb 17, 2023.","No Advisory Committee meeting or REMS needed after mid-cycle review; EMA Pediatric Committee gave positive opinion.","R&D spent $11.5M (Q3 2022); pipeline: KB407 (CF) IND accepted, dosing starts Q4 2022; KB105, KB104, KB301 advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-22-000061","json":"https://secwatch.observer/filing/0001711279-22-000061.json","markdown":"https://secwatch.observer/filing/0001711279-22-000061.md","text":"https://secwatch.observer/filing/0001711279-22-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000061/0001711279-22-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000061/krys-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:36:09.334684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d2decf880704293584984ee1b510a5b6773642c","claim":"Krystal Biotech, Inc. reported the third quarter ended September 30, 2022 results: net income $29.9 million, EPS $(1.17) per common share (basic and diluted).","evidence_excerpt":"Net losses for the quarters ended September 30, 2022 and 2021 were $29.9 million and $15.6 million, or $(1.17) and $(0.70), respectively, per common share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000061/0001711279-22-000061-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$29.9 million"},{"label":"EPS","value":"$(1.17) per common share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}